What is the 13F Pro Quality Score for TRAW?

13F Pro ranks Traws Pharma, Inc. (TRAW) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TRAW's current score at https://13fpro.ai/research/TRAW (free sign-up required for the full ranking).

Which hedge funds own the most TRAW stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of TRAW include ADAGE CAPITAL PARTNERS GP, L.L.C., Ikarian Capital,, ORBIMED ADVISORS. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/TRAW as soon as new 13F filings post.

Where does 13F Pro source TRAW data?

All Traws Pharma, Inc. fundamentals and ownership data come directly from SEC EDGAR. Traws Pharma, Inc. files with the SEC under CIK 1130598. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TRAW in?

Traws Pharma, Inc. (TRAW) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is TRAW research updated on 13F Pro?

TRAW's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Traws Pharma, Inc.(TRAW)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1130598 TRAW stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $46.2M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

TRAW Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Traws Pharma, Inc. (TRAW), a Healthcare sector company. TRAW is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $46.2m in revenue. Based on the latest XBRL financial filings (Q1 2026), Traws Pharma, Inc. reports net income of $-7.1M, free cash flow of $-2.6M. Top institutional holders of TRAW by reported 13-F value include ADAGE CAPITAL PARTNERS GP, L.L.C., Ikarian Capital,, ORBIMED ADVISORS, based on the most recent SEC filings. TRAW trades on the Nasdaq exchange and files with the SEC under CIK 1130598. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TRAW daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Traws Pharma, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-7.1M

Free Cash Flow

Q1 2026

$-2.6M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+1134.5% YoY

$2.8MFY 2025

FY20 $231.0KFY23 $226.0KFY24 $226.0KFY25 $2.8M

Net Income

+105.5% YoY

$9.2MFY 2025

FY20 $-25.2MFY23 $-18.9MFY24 $-166.5MFY25 $9.2M

Operating Income

+87.4% YoY

$-17.9MFY 2025

FY20 $-25.0MFY23 $-20.3MFY24 $-142.4MFY25 $-17.9M

EPS (Diluted)

+102.3% YoY

$0.82FY 2025

FY20 $-2.17FY23 $-22.57FY24 $-35.21FY25 $0.82

Total Assets

-57.5% YoY

$10.6MFY 2025

FY20 $20.0MFY23 $22.7MFY24 $25.0MFY25 $10.6M

Op. Cash Flow

+39.0% YoY

$-18.2MFY 2025

FY20 $-23.1MFY23 $-17.9MFY24 $-29.8MFY25 $-18.2M

Metric	FY 2025	FY 2024	FY 2023	FY 2020	FY 2019	FY 2018
Revenue	$2.8M +1134.5%	$226.0K +0.0%	$226.0K -2.2%	$231.0K -89.4%	$2.2M +77.8%	$1.2M
Net Income	$9.2M +105.5%	$-166.5M -778.8%	$-18.9M +24.7%	$-25.2M -17.0%	$-21.5M -4.5%	$-20.6M
Operating Income	$-17.9M +87.4%	$-142.4M -601.4%	$-20.3M +18.8%	$-25.0M -15.2%	$-21.7M +6.8%	$-23.3M
EPS (Diluted)	$0.82 +102.3%	$-35.21 -56.0%	$-22.57 -940.1%	$-2.17	—	—
Total Assets	$10.6M -57.5%	$25.0M +10.0%	$22.7M +13.5%	$20.0M -15.6%	$23.7M +32.1%	$17.9M
Operating Cash Flow	$-18.2M +39.0%	$-29.8M -66.1%	$-17.9M +22.3%	$-23.1M -10.8%	$-20.8M +8.2%	$-22.7M

AI Insight: TRAW Financial Trends

Traws showed a dramatic swing to profitability in Q4 2025 with $146M net income and $119M operating income, but revenue remains near-zero and profitability has already reversed in Q1 2026.

• Q4 2025 net income surged to $146M and operating income to $119M, reversing six consecutive quarters of losses.

• Operating cash flow turned positive at $8M in Q4 2025, first positive quarter since at least Q1 2024.

• Revenue remains essentially flat near $0M across all eight quarters; Q2 and Q4 2025 both recorded only $3M.

⚠ Q4 2025 profitability has already reversed: Q1 2026 shows $-7M net income and $-7M operating income.

⚠ Massive Q4 2025 earnings spike without corresponding revenue growth suggests one-time gain or non-cash benefit.

AI Insight: TRAW Ratio Trends

Insufficient data to establish meaningful trends; only Q2 2025 shows metrics, all deeply negative.

• Q2 2025 reveals severe profitability stress: operating margin −45.7%, net margin −33.5%, ROA −23.4%.

⚠ Single data point (Q2 2025) insufficient to confirm trend direction or recovery trajectory.

Get alerted when TRAW's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Traws Pharma, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TRAW

ADAGE CAPITAL PARTNERS GP, L.L.C.
$1.3M730,000 sh
Ikarian Capital, LLC
$1.2M678,142 sh
ORBIMED ADVISORS LLC
$1.1M605,531 sh
Squadron Capital Management LLC
$936.4K511,714 sh
Dauntless Investment Group, LLC
$763.1K416,998 sh
BOOTHBAY FUND MANAGEMENT, LLC
$356.0K194,536 sh
ADAR1 Capital Management, LLC
$282.0K154,098 sh
GEODE CAPITAL MANAGEMENT, LLC
$141.1K77,103 sh
Palumbo Wealth Management LLC
$112.0K61,175 sh
VANGUARD CAPITAL MANAGEMENT LLC
$101.0K55,193 sh

Fund	Value	Shares
ADAGE CAPITAL PARTNERS GP, L.L.C.	$1.3M	730,000
Ikarian Capital, LLC	$1.2M	678,142
ORBIMED ADVISORS LLC	$1.1M	605,531
Squadron Capital Management LLC	$936.4K	511,714
Dauntless Investment Group, LLC	$763.1K	416,998
BOOTHBAY FUND MANAGEMENT, LLC	$356.0K	194,536
ADAR1 Capital Management, LLC	$282.0K	154,098
GEODE CAPITAL MANAGEMENT, LLC	$141.1K	77,103
Palumbo Wealth Management LLC	$112.0K	61,175
VANGUARD CAPITAL MANAGEMENT LLC	$101.0K	55,193

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TRAW on your watchlist

Track score changes the day Traws Pharma, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TRAW a good stock to buy?

13F Pro's AI-powered analysis of Traws Pharma, Inc. (TRAW) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TRAW are available on the TRAW stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own TRAW?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TRAW. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Traws Pharma, Inc.'s investment landscape.